Tibotec's HIV drug TMC125 effective in Ph IIb trials.(Tibotec Pharmaceuticals)(Brief Article)

In a presentation to the recent Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Washington DC, USA, Ireland-based Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson, reported the results with TMC125, a non-nucleoside reverse transcriptase inhibitor in HIV-1 patients with drug resistance.

TMC125 was assessed in a Phase IIb dose-ranging, randomized, partially-blinded examination in 199 HIV-1 patients with substantial treatment exposure. The mean change from baseline in …